methyl 2-[(3R,6R)-6-methyl-1-[2-(triazol-2-yl)benzoyl]piperidin-3-yl]oxy-4-propylpyridine-3-carboxylate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-[(3R,6R)-6-methyl-1-[2-(triazol-2-yl)benzoyl]piperidin-3-yl]oxy-4-propylpyridine-3-carboxylate
• 化学式: C₂₅H₂₉N₅O₄
• 分子量: 463.5
• InChiKey: ZWLABYBSKPFHAG-IEBWSBKVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  99.4
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• 3-ESTER-4-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2934516A1

  公开（公告）日：2015-10-28
• METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：EP3218007A1

  公开（公告）日：2017-09-20
• [EN] 3-ESTER-4-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE 3-ESTER-4-SUBSTITUÉS
  申请人：MERCK SHARP & DOHME

  公开号：WO2014099697A1

  公开（公告）日：2014-06-26

  The present invention is directed to 3-ester-4-substituted compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 3-ester-4-substituted compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
• [EN] METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER<br/>[FR] MÉTHODES ET COMPOSITIONS PHARMACEUTIQUES POUR LE TRAITEMENT DU CANCER
  申请人：INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE

  公开号：WO2016075134A1

  公开（公告）日：2016-05-19

  The present invention relates to methods and pharmaceutical compositions for the treatment of cancer. More particularly, the present invention relates to a method of treating cancer in subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R antagonist.